Soft tissue and skeletal involvement in FIP1L1-PDGFR-alpha positive chronic eosinophilic leukemia: imatinib mesylate may induce complete molecular and imaging remission
Malagola, M.; Martinelli, G.; Rondoni, M.; Ottaviani, E.; Piccaluga, P.Paolo.; Ricci, P.; Visani, G.; Baccarani, M.
Haematologica 89(8): Ecr25
2004
ISSN/ISBN: 0390-6078 PMID: 15339694 Document Number: 580323
Document emailed within 1 workday
Related Documents
Jentsch-Ullrich, K.; Pelz, A-Friederike.; Braun, H.; Koenigsmann, M.; Mohren, M.; Wieacker, P.; Franke, A. 2004: Complete molecular remission in a patient with Philadelphia-chromosome positive acute myeloid leukemia after conventional therapy and imatinib Haematologica 89(5): Ecr15Cools, J. 2005: FIP1L1-PDGFR alpha, a therapeutic target for the treatment of chronic eosinophilic leukemia Verhandelingen - Koninklijke Academie Voor Geneeskunde van Belgie 67(3): 169-176
Casado, L.F.; Picó, M.; Gómez, C.; Ferro, M.T.; Fernández-Rañada, J.M.; Steegmann, J.L. 1997: Fluctuating molecular remission in patients with chronic myeloid leukemia with long term complete cytogenetic response after alpha interferon treatment Medicina Clinica 109(7): 251-255
Sacha, T.; Czekalska, S.; Foryciarz, K.; Zawada, M.; Florek, I.; Cwynar, D.; Wator, G.; Balwierz, W.; Skotnicki, A.B. 2011: H-oCT1 gene expression as a predictor of major and complete molecular response to imatinib of chronic myeloid leukemia. Single center experience Przeglad Lekarski 68(4): 191-195
Deshmukh, C.; Saikia, T.; Bakshi, A.; Amare-Kadam, P.; Baisane, C.; Parikh, P. 2005: Imatinib mesylate in chronic myeloid leukemia: a prospective, single arm, non-randomized study Journal of the Association of Physicians of India 53: 291-295
Scheinfeld, N. 2006: Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate Journal of Drugs in Dermatology: Jdd 5(3): 228-231
Sung, Y.; Kim, M.Hee.; Cho, E. 2019: Successful hyaluronic acid filler injection in a chronic myeloid leukemia patient taking imatinib mesylate Journal of Cosmetic and Laser Therapy 21(4): 243-244
Cervantes, F.; Hernández-Boluda, J-Carlos.; Steegmann, J-Luis.; Conde, E.; Alvarez-Larrán, A.; López-Jiménez, J.; Osorio, S.; Villalón, Lía.; Camós, M.; García-Conde, J.; Odriozola, Jús. 2003: Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients Haematologica 88(10): 1117-1122
Piccaluga, P.Paolo.; Martinelli, G.; Malagola, M.; Rondoni, M.; Bianchini, M.; Visani, G.; Baccarani, M. 2003: Complete remission in acute myeloid leukemia with granulocyte-colony stimulating factor without chemotherapy. Report of cytogenetic remission of a t(9;11)(p22q23) positive AML patient and review of literature Haematologica 88(8): Ecr28
Usman, M.; Kakepoto, G.N.; Adil, S.N.; Sajid, R.; Arain, S.; Khurshid, M. 2004: Hematologic and cytogenetic findings in eleven chronic myelogenous leukemia patients treated with imatinib mesylate at a tertiary care hospital Jpma. Journal of the Pakistan Medical Association 54(1): 17-20
Usman, M.; Syed, N.N.; Kakepoto, G.N.; Adil, S.N.; Khurshid, M. 2007: Chronic phase chronic myeloid leukemia: response of imatinib mesylate and significance of Sokal score, age and disease duration in predicting the hematological and cytogenetic response Journal of the Association of Physicians of India 55: 103-107
Weisser, M.; Tischer, J.; Schnittger, S.; Schoch, C.; Ledderose, G.; Kolb, H.Jochem. 2006: A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation Haematologica 91(5): 663-666
Pectasides, D.; Nikolaou, M.; Pectasides, E.; Koumarianou, A.; Valavanis, C.; Economopoulos, T. 2008: Complete response after imatinib mesylate administration in a patient with chemoresistant stage IV seminoma Anticancer Research 28(4c): 2317-2320
Luciano, L.; Catalano, L.; Sarrantonio, C.; Guerriero, A.; Califano, C.; Rotoli, B. 1999: AlphaIFN-induced hematologic and cytogenetic remission in chronic eosinophilic leukemia with t(1;5) Haematologica 84(7): 651-653
Rediti, M.; Pellegrini, E.; Molinara, E.; Cerullo, C.; Fonte, C.; Lunghi, A.; Iori, A.; Neri, B. 2014: Complete pathological response in advanced extra-gastrointestinal stromal tumor after imatinib mesylate therapy: a case report Anticancer Research 34(2): 905-907
Ho, A.D.; Reichardt, P.; Gamm, H.; Hunstein, W. 1990: Pleural involvement in hairy cell leukemia--development under alpha-interferon and remission upon pentostatin therapy Leukemia 4(10): 720-721
Gatto, S.; Scappini, B.; Pham, L.; Onida, F.; Milella, M.; Ball, G.; Ricci, C.; Divoky, V.; Verstovsek, S.; Kantarjian, H.M.; Keating, M.J.; Cortes-Franco, J.E.; Beran, M. 2003: The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate Haematologica 88(8): 853-863
Molnár, L.; Nagy, A.; Dávid, M.; Szomor, A.ád.; Méhes, G.áb.; Kovács, G.áb.; Losonczy, H. 2004: Results of imatinib therapy in late-stage chronic myeloid leukemia after treatment with interferon-alpha Orvosi Hetilap 145(17): 901-907
Solal-Celigny, P.; Schuller, E.; Courouble, Y.; Gislon, J.; Elghozi, D.; Boivin, P. 1983: Cerebromeningeal location of chronic lymphoid leukemia. Rapid immunochemical diagnosis and complete remission by intrathecal chemotherapy Presse Medicale 12(37): 2323-2325
Grcevska, L.; Polenakovic, M. 1999: A long-term follow-up (21 years) of a patient with class IIi lupus nephritis - complete remission of the renal involvement and death because of CNS involvement Clinical Nephrology 52(6): 394-397